Gyre Therapeutics, Inc. GYRE
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.71% | 11.70% | 21.09% | 13.05% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.71% | 11.70% | 21.09% | 13.05% | -- |
| Cost of Revenue | 62.85% | 51.33% | 39.44% | 22.57% | -- |
| Gross Profit | 4.57% | 10.27% | 20.39% | 12.68% | -- |
| SG&A Expenses | 18.12% | 26.36% | 24.53% | 7.28% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.72% | 31.74% | 34.84% | 17.11% | -- |
| Operating Income | -473.32% | -172.75% | -54.72% | -23.96% | -- |
| Income Before Tax | -377.70% | -172.64% | -49.06% | 116.27% | -- |
| Income Tax Expenses | 18.94% | 14.39% | -14.36% | -40.53% | -- |
| Earnings from Continuing Operations | -561.55% | -225.92% | -59.37% | 111.01% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 3,695.90% | 334.16% | 99.33% | 93.24% | -- |
| Net Income | -398.49% | -184.01% | -40.15% | 109.97% | -- |
| EBIT | -473.32% | -172.75% | -54.72% | -23.96% | -- |
| EBITDA | -306.92% | -138.35% | -42.55% | -10.10% | -- |
| EPS Basic | -1,759.72% | -285.75% | -83.79% | 103.29% | -- |
| Normalized Basic EPS | -132.88% | -38.02% | -24.03% | 420.68% | -- |
| EPS Diluted | -1,410.84% | -1,161.90% | -127.91% | 100.39% | -- |
| Normalized Diluted EPS | -138.90% | -36.94% | -11.16% | 279.17% | -- |
| Average Basic Shares Outstanding | 8.04% | 5.82% | 4.77% | 7.47% | -- |
| Average Diluted Shares Outstanding | 6.52% | -0.20% | -5.95% | -4.00% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |